In this guide
- What is myopia, and why does controlling it matter?
- What is repeated low-level red-light therapy?
- Does red light therapy work for myopia control?
- Is red light therapy safe for children’s eyes?
- What happens when red light therapy is stopped?
- How does RLRL compare with other myopia-control options?
- What should parents ask before considering RLRL?
- Do outdoor time and visual habits still matter?
- Frequently asked questions
- Make an informed decision about your child’s vision
Laxmi Opticians Education Center • Evidence checked: 11 October 2026
If your child’s spectacle number keeps increasing, you may have come across red light therapy for myopia control. Research suggests that repeated low-level red-light therapy, or RLRL, can slow the progression of childhood myopia. However, questions about retinal safety, differences between devices and what happens after treatment stops remain unresolved. It should not be presented as a cure or a treatment to try without professional guidance. International Myopia Institute’s 2025 assessment.
This guide explains the findings behind the headlines and the questions worth discussing with your child’s eye-care professional.
What is myopia, and why does controlling it matter?
Myopia, also called short-sightedness or near-sightedness, makes distant objects appear blurred. Light focuses in front of the retina rather than on it, often because the eye is too long. Children can become more short-sighted as their eyes grow. Standard spectacles correct blurred vision; myopia-control treatments aim to reduce how quickly the condition progresses. AAPOS guide to childhood myopia.
The concern goes beyond needing stronger glasses. High myopia is associated with greater risks of retinal tears, retinal detachment and other sight-threatening changes later in life. Regular eye-health examinations remain important even when vision is clear with glasses. AAPOS guide to progressive high myopia.
What is repeated low-level red-light therapy?
RLRL uses a purpose-designed device to deliver red light to the eyes. A major trial studied light around 650 nanometres, with children continuing their prescribed spectacles. Its results apply to the studied device and protocol. Jiang and colleagues’ randomised trial.
Researchers are investigating whether red light changes retinal metabolism, blood flow in the choroid—the vascular layer behind the retina—and signals involved in eye growth. These are proposed mechanisms, not a settled explanation. Changes in eye measurements do not establish that myopia has been permanently reversed. Research update on mechanisms and safety.
Does red light therapy work for myopia control?
Several randomised trials have reported meaningful benefits. One widely cited study enrolled 264 children aged 8–13 years in China and compared RLRL plus single-vision spectacles with spectacles alone.
At 12 months, the adjusted average results were:
| Outcome | RLRL plus spectacles | Single-vision spectacles alone |
|---|---|---|
| Increase in axial length—the eye’s front-to-back length | 0.13 mm | 0.38 mm |
| Change towards a more myopic prescription | −0.20 D | −0.79 D |
These results support an effect on progression. They do not mean every child will respond similarly, become spectacle-free or have no future eye-health risk. The comparison was with ordinary single-vision spectacles, not every available myopia-control treatment. 2022 multicentre trial.
A separate 2024 randomised trial also reported substantially less axial elongation, including average axial shortening in its treatment group. Shortening measured during treatment should not be advertised as a permanent cure: persistence after stopping and long-term clinical outcomes require separate evidence. 2024 JAMA Ophthalmology trial.
How should parents interpret effectiveness claims?
Look beyond a headline percentage. Ask which children were studied, which device was used, how long follow-up lasted and what the comparison treatment was. A large benefit against ordinary glasses does not automatically prove superiority over modern myopia-control lenses or a particular atropine concentration.
Much of the evidence comes from Chinese children. Evidence from other populations is developing, including an Australian pilot trial, but larger and longer studies remain important. Results from one setting cannot simply be assumed for every child in India. Australian pilot randomised trial.
Is red light therapy safe for children’s eyes?
Long-term retinal safety remains an open question. The retina is the light-sensitive tissue at the back of the eye, so both visual function and retinal structure matter when assessing treatment.
An earlier safety review included 20 studies, with a median duration of nine months and a maximum of two years. It found no reported irreversible visual loss in the included evidence, but called for longer, adequately powered studies. Short-term reassurance is useful; it cannot exclude rare problems or effects from repeated exposure over many years. 2024 systematic safety review.
What safety concerns have been reported?
A 2023 case report described retinal injury and reduced vision in a 12-year-old after several months of RLRL use. A case report cannot establish how often an event occurs, but it is an important signal that harm is possible. Retinal damage case report.
A 2025 observational study found lower cone photoreceptor density near the centre of the retina in some treated children. Cones support detailed and colour vision. The study raises concern, but its design does not establish cause and effect, and imaging methods have been questioned in subsequent scientific correspondence. 2025 cone-density study, published imaging-method critique.
There are also reassuring findings. A small 2026 cross-sectional study, including 20 treated eyes with at least eight months of exposure, did not identify significant cone-density loss or retinal microvascular problems associated with treatment. Because it compared groups at one point in time, it cannot settle the long-term safety debate. 2026 retinal imaging study.
Why the exact device matters
A 2026 laboratory assessment of four devices found substantial differences in optical output. Under the tested conditions, two laser devices reached specified safety limits sooner than the commonly studied three-minute exposure, while the tested LED device remained within limits for much longer. These were laboratory findings, not measurements of injury rates in children. Nor do they establish equivalent treatment effectiveness for the LED device. 2026 device-safety study.
For parents, the practical implication is to ask for evidence about the exact device, treatment protocol and monitoring plan, rather than relying on the phrase “low-level red light”. Do not use a household lamp, laser pointer or skin-treatment device as a substitute.
What happens when red light therapy is stopped?
Some studies report a rebound effect: faster progression after treatment ends. In a two-year follow-up study, children who stopped RLRL had an average second-year axial increase of 0.42 mm, compared with 0.28 mm in children who used single-vision spectacles throughout.
The second-year groups were small and were not newly randomised, so these figures should not be treated as a prediction for an individual child. They do show why a treatment plan needs to address monitoring and eventual discontinuation. Two-year follow-up and rebound study.
How does RLRL compare with other myopia-control options?
Families should discuss the full range of appropriate treatments rather than choosing from a single advertisement.
| Option | What parents should know |
|---|---|
| Myopia-control spectacle lenses | Special designs have evidence for slowing progression; ordinary single-vision glasses are different. |
| Myopia-control soft contact lenses | Certain designs can slow progression and require suitable fitting and careful hygiene. |
| Orthokeratology | Overnight lenses reshape the cornea temporarily and can slow axial elongation; hygiene and follow-up are essential. |
| Low-dose atropine | Prescription eye drops can slow progression; concentration, side effects and suitability need clinical assessment. |
| Repeated low-level red light | Trials show benefit, but retinal safety, device differences and rebound require particular attention. |
There is no universal best choice. Age, progression, eye health and ability to follow treatment all matter. IMI assessment of interventions, AAPOS treatment guide.
What should parents ask before considering RLRL?
Take recent and previous prescriptions to your appointment and ask:
- How quickly is my child’s myopia progressing, and can axial length be measured?
- What evidence supports this particular device for children like mine?
- What is its current authorisation for this use in India?
- Why consider it instead of other available treatments?
- What baseline retinal checks and follow-up examinations are needed?
- Which symptoms mean treatment should stop, and whom should we contact?
- How will progression be monitored if treatment is discontinued?
A published trial is not proof of local regulatory authorisation. Device-specific status should be verified before treatment is offered.
If a child using RLRL develops reduced or distorted vision, a new central dark spot or an unusually persistent afterimage, stop using the device and seek prompt ophthalmic assessment. Do not increase exposure or continue through visual symptoms. Retinal imaging and visual monitoring have been recommended to help detect adverse effects. Safety review and monitoring recommendations.
Do outdoor time and visual habits still matter?
Yes. The International Myopia Institute recommends at least two hours outdoors daily to help delay myopia onset. This evidence is stronger for preventing or delaying myopia than for treating established progression. Outdoor activity complements clinical care; it does not replace a prescribed treatment. Use appropriate sun protection and never look directly at the sun. IMI guidance on light and outdoor activity.
Encourage breaks from prolonged close work, a comfortable reading distance and consistent use of the prescribed correction. Your eye-care professional can advise how often your child needs review. IMI clinical management guidance.
Frequently asked questions
Can red light therapy cure myopia permanently?
Current evidence does not establish a permanent cure. The aim is to slow progression, and improvement during treatment does not guarantee lasting reversal after it stops. RLRL evidence update.
Can my child stop wearing glasses during treatment?
Do not change your child’s prescribed correction without advice. Red light therapy is not a replacement for the glasses needed for clear vision. IMI clinical management guidance.
Is a red LED panel the same as a myopia-treatment device?
No. Optical output and delivery vary substantially between devices. Evidence for one instrument cannot be transferred to an unrelated panel or lamp. Device comparison study.
Does red light therapy work for adults?
Most myopia-control evidence concerns children. It should not be assumed to reverse adult myopia or remove an adult’s need for spectacles. RLRL evidence update.
Make an informed decision about your child’s vision
An increasing spectacle number deserves a discussion about progression and eye health. Bring your child’s prescription history to your next eye-care appointment and ask about an individual myopia-management plan.
Explore the Laxmi Opticians Education Center for clear explanations of children’s vision, spectacle lenses and myopia management—so you can approach that discussion with better questions.
This article provides general education and does not replace an individual examination or prescription. It does not indicate that Laxmi Opticians offers or endorses RLRL treatment.
